## CITATION REPORT List of articles citing



DOI: 10.1080/15563650902752376 Clinical Toxicology, 2009, 47, 101-11.

Source: https://exaly.com/paper-pdf/46641711/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
184	Valproic Acid-induced myoclonus in a demented patient: a case report. <b>2009</b> , 2009, 392091		5
183	The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status. <b>2009</b> , 86, 32-41		30
182	Extracorporeal elimination in acute valproic acid poisoning. Clinical Toxicology, 2009, 47, 609-16	2.9	27
181	Drug-induced nutrient deficiencies. <b>2009</b> , 56, 1211-24		6
180	Erreur de retranscription des ordonnances en plaiatrie : 🏻 propos dun cas. 2009, 44, 196-199		1
179	Clinical outcomes and low-dose levocarnitine supplementation in psychiatric inpatients with documented hypocarnitinemia: a retrospective chart review. <b>2010</b> , 16, 5-14		11
178	Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo. <b>2010</b> , 51, 603-14		88
177	Enzymology of the carnitine biosynthesis pathway. <b>2010</b> , 62, 357-62		56
176	Review article: drug-induced liver injury in clinical practice. <b>2010</b> , 32, 3-13		94
175	Doxorubicin toxicity can be ameliorated during antioxidant L-carnitine supplementation. <b>2010</b> , 3, 428-3	33	49
174	Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy. <b>2010</b> , 19, 2005-14		77
173	Valproate-induced hyperammonemic encephalopathy, rapidly improved by i.v. carnitine and glucose/thiamine. <b>2010</b> , 45, 762-3		4
172	Intoxication grave Ilacide valproque : place du traitement antidotique et de la uration extracorporelle. <b>2010</b> , 19, 587-592		3
171	Valproate semisodium ER for migraine and cluster headache prophylaxis. <b>2010</b> , 6, 495-504		16
170	Antiepileptic drugs. <b>2011</b> , 33, 125-204		1
169	Eicosapentaenoic acid ablates valproate-induced liver oxidative stress and cellular derangement without altering its clearance rate: dynamic synergy and therapeutic utility. <b>2011</b> , 1811, 460-7		15
168	Progressive encephalopathy with cerebral oedema and infarctions associated with valproate and diazepam overdose. <b>2011</b> , 18, 710-1		9

167	New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 426-34	74
166	Valproate-induced hyperammonemia and seizures: perioperative concerns. <b>2011</b> , 21, 1084-5	6
165	Anesthesia for a child suffering from a deletion in the Xp21 loci resulting in Duchenne disease, glycerol kinase deficiency, and congenital adrenal hypoplasia. <b>2011</b> , 21, 1085-7	2
164	L-carnitine increases survival in a murine model of severe verapamil toxicity. <b>2011</b> , 18, 1135-40	3
163	Effects of valproic acid on organic acid metabolism in children: a metabolic profiling study. <b>2011</b> , 89, 867-74	29
162	Valproic acid-associated acute liver failure in children: case report and analysis of liver transplantation outcomes in the United States. <b>2011</b> , 158, 802-7	31
161	Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid. <b>2011</b> , 11, 36	29
160	Influencing clinical practice regarding the use of antiepileptic medications during pregnancy: modeling the potential impact on the prevalences of spina bifida and cleft palate in the United States. <b>2011</b> , 157C, 234-46	23
159	Severe rhabdomyolysis caused by valproic Acid in a neonate with seizures and chromosomal abnormalities. <b>2011</b> , 223, 434-5	7
158	Valproate-induced worsening of seizures: clue to underlying diagnosis. <b>2011</b> , 26, 1319-21	11
157	The embryonic stem cell test as tool to assess structure-dependent teratogenicity: the case of valproic acid. <b>2011</b> , 120, 360-70	28
156	Animal models of idiosyncratic drug-induced liver injurycurrent status. <b>2011</b> , 41, 723-39	51
155	The consequences of valproate overdose. <b>2011</b> , 57, 1233-7	10
154	Case Studies in Epilepsy: Common and Uncommon Presentations. 44-45	
153	Effects of vitamin U (S-methyl methionine sulphonium chloride) on valproic acid induced liver injury in rats. <b>2012</b> , 50, 3562-6	38
152	Miscellaneous central nervous system intoxicants. <b>2012</b> , 28, 587-600	1
151	Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy. 2012, 69, 35-9	63
150	Mitochondrial disease and epilepsy. <b>2012</b> , 54, 397-406	100

149	Effects of L-carnitine against oxidative stress in human hepatocytes: involvement of peroxisome proliferator-activated receptor alpha. <b>2012</b> , 19, 32	96
148	Valproate-induced hyperammonemic encephalopathy: a brief review. <b>2012</b> , 28, 1039-42	53
147	An Update on Drug-induced Liver Injury. <b>2012</b> , 2, 247-59	79
146	Influence of calcium channel blockers on anticonvulsant and antinociceptive activities of valproic acid in pentylenetetrazole-kindled mice. <b>2012</b> , 64, 305-14	23
145	Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. <b>2012</b> , 44, 88-106	575
144	Unilateral basal-ganglia involvement likely due to valproate-induced hyperammonemic encephalopathy. <b>2012</b> , 33, 919-22	1
143	Which psychotropic medications induce hepatotoxicity?. <b>2012</b> , 34, 53-61	14
142	Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management. <b>2012</b> , 34, 290-8	59
141	Anticonvulsants. <b>2012</b> , 40, 96-97	
140	Posterior reversible encephalopathy syndrome in a survivor of valproate-induced acute liver failure: a case report. <b>2013</b> , 7, 144	4
139	Neurobehavioral effects of L-carnitine and its ability to modulate genotoxicity and oxidative stress biomarkers in mice. <b>2013</b> , 110, 40-5	4
138	Clinical and biochemical aspects of primary and secondary hyperammonemic disorders. <b>2013</b> , 536, 101-8	71
137	Bewusstseinsstflungen und Enzephalopathien. <b>2013</b> ,	6
136	Drug-induced liver injury from antiepileptic drugs. <i>Clinics in Liver Disease</i> , <b>2013</b> , 17, 687-97, x 4.6	11
135	High-flux hemodialysis and levocarnitine in the treatment of severe valproic Acid intoxication. <b>2013</b> , 2013, 526469	3
134	Carnitine deficiency and its possible risk factors in TB patients: first report. <b>2013</b> , 5, 945-53	
133	A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel. <b>2013</b> , 1, 31	54
132	Valproic Acid and topiramate induced hyperammonemic encephalopathy in a patient with normal serum carnitine. <b>2013</b> , 18, 128-36	8

131 Drug-induced liver disease. 341-369

130	A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks. <b>2014</b> , 171, 2230-42	47
129	Toxic Ingestions. <b>2014</b> , 695-727	
128	Nutrition as medical therapy. <b>2014</b> , 26, 277-87	2
127	Toxin-induced hepatic injury. <b>2014</b> , 32, 103-25	13
126	XXXIV International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 27B0 May 2014, Brussels, Belgium. <i>Clinical Toxicology</i> , <b>2014</b> , 52, 295-443	16
125	Novel Vitamin K analogs suppress seizures in zebrafish and mouse models of epilepsy. <b>2014</b> , 259, 142-54	31
124	Carnitine for prevention of antituberculosis drug-induced hepatotoxicity: a randomized, clinical trial. <b>2014</b> , 29, 997-1004	20
123	Evidence for a potential protective effect of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity. <b>2014</b> , 7, 211-8	28
122	Valproate-induced liver injury: modulation by the omega-3 fatty acid DHA proposes a novel anticonvulsant regimen. <b>2014</b> , 14, 85-94	31
121	A new perspective on the importance of glycine conjugation in the metabolism of aromatic acids. <b>2014</b> , 46, 343-61	43
120	Acute liver failure after valproate exposure in patients with POLG1 mutations and the prognosis after liver transplantation. <b>2014</b> , 20, 1402-12	48
119	Valproic acid triggers increased mitochondrial biogenesis in POLG-deficient fibroblasts. <b>2014</b> , 112, 57-63	33
118	Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease). <b>2014</b> , 23, 429-34	5
117	Fulminant hepatic failure in the context of reinstituting valproate use. 2014, 55, 303-4	1
116	Usefulness of Levocarnitine and/or Branched-Chain Amino Acids during Invasive Treatment for Hepatocellular Carcinoma. <b>2015</b> , 61, 433-40	9
115	Pronounced reversible hyperammonemic encephalopathy associated with combined valproate-topiramate therapy in a 7-year-old girl. <b>2015</b> , 4, 276	1
114	N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review protocol. <b>2015</b> , 4, 84	11

113	Valproate Induced Delirium due to Hyperammonemia in a Case of Acute Mania: A Diagnostic Dilemma. <b>2015</b> , 9, VD01-VD02	14
112	Idiosyncratic Valproic Acid-Induced Hepatotoxicity in a Sickle Cell Patient. <b>2015</b> , 31, 43-46	1
111	Valproic acid-induced hepatotoxicity in Alpers syndrome is associated with mitochondrial permeability transition pore opening-dependent apoptotic sensitivity in an induced pluripotent stem cell model. <b>2015</b> , 61, 1730-9	69
110	Extracorporeal treatment for valproic acid poisoning: systematic review and recommendations from the EXTRIP workgroup. <i>Clinical Toxicology</i> , <b>2015</b> , 53, 454-65	61
109	[Hemoperfusion with activated charcoal on valproic acid poisoning. A case report]. 2015, 39, 449-51	2
108	A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation. <b>2015</b> , 54, 305-17	35
107	Valproic acid. <b>2016</b> , 303-337	
106	Carnitine and derivatives. <b>2016</b> , 161-165	
105	Carnitine and/or Acetylcarnitine Deficiency as a Cause of Higher Levels of Ammonia. <b>2016</b> , 2016, 2920108	21
104	The HepaRG cell line, a superior in vitro model to L-02, HepG2 and hiHeps cell lines for assessing drug-induced liver injury. <b>2016</b> , 32, 37-59	41
103	Environmental, dietary and case-control study of Nodding Syndrome in Uganda: A post-measles brain disorder triggered by malnutrition?. <b>2016</b> , 369, 191-203	36
102	N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review. <b>2016</b> , 81, 1021-9	34
101	Hyperammonemia induced by prophylactic administration of antiepileptic drugs during the perioperative period of craniotomy. <b>2016</b> , 462, 33-39	1
100	l-carnitine protects human hepatocytes from oxidative stress-induced toxicity through Akt-mediated activation of Nrf2 signaling pathway. <b>2016</b> , 94, 517-25	13
99	Anticonvulsants. <b>2016</b> , 44, 133-134	
98	Defining 'nutraceuticals': neither nutritious nor pharmaceutical. <b>2017</b> , 83, 8-19	105
97	Population pharmacokinetic modelling of valproic acid and its selected metabolites in acute VPA poisoning. <b>2017</b> , 69, 340-349	9
96	L-Arginine in the treatment of valproate overdose - five clinical cases. <i>Clinical Toxicology</i> , <b>2017</b> , 55, 260-2 <u>66</u>	5

## (2018-2017)

95	The effect of VPA on bone: From clinical studies to cell cultures-The molecular mechanisms revisited. <b>2017</b> , 48, 36-43	16
94	Valproate induced hepatic steatosis by enhanced fatty acid uptake and triglyceride synthesis. <b>2017</b> , 324, 12-25	22
93	Valproate-Induced Hyperammonemic Encephalopathy in General Hospital Patients With One or More Psychiatric Disorders. <b>2017</b> , 58, 415-420	12
92	Antiepileptic Drugs and Liver Disease. <b>2017</b> , 77, 23-36	37
91	Valproic Acid Overdose Review of a Case With Electrocardiographic Changes. 2017, 53, 333-338	2
90	A mass spectrometry-based strategy combined with bioinformatics: A simple preclinical model for profiling valproic-acid-induced major proteins and modifications in human liver cells. <b>2017</b> , 58, 78-84	
89	Neurotoxicity of Ammonia. 2017, 42, 713-720	39
88	Antidote availability in the municipality of Campinas, SB Paulo, Brazil. <b>2017</b> , 135, 15-22	4
87	High-throughput determination of valproate in human samples by modified QuEChERS extraction and GC-MS/MS. <b>2018</b> , 31, 66-73	9
86	Antiepileptic drugs: Role in paediatric poisoning. <b>2018</b> , 54, 475-479	O
85	Why and when to measure ammonemia in cirrhosis?. <b>2018</b> , 42, 505-511	9
84	Mechanism of valproic acid-induced Fanconi syndrome involves mitochondrial dysfunction and oxidative stress in rat kidney. <i>Nephrology</i> , <b>2018</b> , 23, 351-361	49
83	Valproic acid-induced hyperammonemia: Incidence, clinical significance, and treatment management. <i>Mental Health Clinician</i> , <b>2018</b> , 8, 73-77	20
82	Multifactorial non-cirrhotic hyperammonaemic encephalopathy. <i>BMJ Case Reports</i> , <b>2018</b> , 2018, 0.9	5
81	A 33-Year-Old Woman With Altered Mental Status and Elevated Ammonia Level. <i>Chest</i> , <b>2018</b> , 154, e169- <b>g</b> .‡71	1
80	Idiosyncratic Drug-Induced Liver Injury: Mechanisms and Susceptibility Factors. <b>2018</b> , 625-650	
79	Carnitine Deficiency in Chinese Children with Epilepsy on Valproate Monotherapy. <i>Indian Pediatrics</i> , <b>2018</b> , 55, 222-224	2
78	Refining the Benefit/Risk Profile of Anti-Epileptic Drugs in Headache Disorders. <i>CNS Drugs</i> , <b>2018</b> , 32, 735-746	4

77	Levocarnitine for valproate-induced hyperammonemia in the psychiatric setting: A case series and literature review. <i>Mental Health Clinician</i> , <b>2018</b> , 8, 148-154	1.6	10
76	Endoplasmic Reticulum Stress-Induced Upregulation of STARD1 Promotes Acetaminophen-Induced Acute Liver Failure. <i>Gastroenterology</i> , <b>2019</b> , 157, 552-568	13.3	39
75	Rhabdomyolysis and Hepatotoxicity From Valproic Acid: Case Reports. <i>Journal of Pharmacy Practice</i> , <b>2021</b> , 34, 648-652	1.3	2
74	Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy. <i>Cells</i> , <b>2019</b> , 8,	7.9	13
73	Carnitine Inborn Errors of Metabolism. <i>Molecules</i> , <b>2019</b> , 24,	4.8	38
72	Characterizing acyl-carnitine biosignatures for schizophrenia: a longitudinal pre- and post-treatment study. <i>Translational Psychiatry</i> , <b>2019</b> , 9, 19	8.6	27
71	Potential biomarker of fibroblast growth factor 21 in valproic acid-treated livers. <i>BioFactors</i> , <b>2019</b> , 45, 740-749	6.1	16
70	EASL Clinical Practice Guidelines: Drug-induced liver injury. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 1222-1261	13.4	327
69	Efficacy and Safety of Valproic Acid for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis. <i>CNS Drugs</i> , <b>2019</b> , 33, 239-250	6.7	7
68	Levocarnitine for the Treatment of Valproic Acid-Induced Hyperammonemic Encephalopathy in Children: The Experience of a Large, Tertiary Care Pediatric Hospital and a Poison Center. <i>American Journal of Therapeutics</i> , <b>2019</b> , 26, e344-e349	1	7
67	Frequent Offenders and Patterns of Injury. Clinics in Liver Disease, 2020, 24, 37-48	4.6	3
66	Butyrate prevents valproate-induced liver injury: In vitro and in vivo evidence. <i>FASEB Journal</i> , <b>2020</b> , 34, 676-690	0.9	21
65	Selenium and L-carnitine protects from valproic acid-Induced oxidative stress and mitochondrial damages in rat cortical neurons. <i>Drug and Chemical Toxicology</i> , <b>2020</b> , 1-8	2.3	8
64	Drug induced liver injury: an update. <i>Archives of Toxicology</i> , <b>2020</b> , 94, 3381-3407	5.8	40
63	Valproic acid promotes mitochondrial dysfunction in primary human hepatocytes in vitro; impact of C/EBP&controlled gene expression. <i>Archives of Toxicology</i> , <b>2020</b> , 94, 3463-3473	5.8	1
62	Drug-Induced Liver Injury in GI Practice. <i>Hepatology Communications</i> , <b>2020</b> , 4, 631-645	6	20
61	Valproic acid up-regulates the whole NO-citrulline cycle for potent iNOS-NO signaling to promote neuronal differentiation of adipose tissue-derived stem cells. <i>Nitric Oxide - Biology and Chemistry</i> , <b>2021</b> , 106, 35-44	5	2
60	L-Carnitine and Acylcarnitines: Mitochondrial Biomarkers for Precision Medicine. <i>Metabolites</i> , <b>2021</b> , 11,	5.6	32

59 Drug- or toxin-induced mitochondrial toxicity. **2021**, 203-220

58	Relevante Aspekte der arzneimittelassoziierten Hepatotoxizitlim klinischen Alltag. <i>Nervenheilkunde</i> , <b>2021</b> , 40, 43-47	0.3	
57	Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. <i>Hepatology International</i> , <b>2021</b> , 15, 258-282	8.8	15
56	Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. <i>Pharmacological Research</i> , <b>2021</b> , 164, 105404	10.2	9
55	Drug-Induced Liver Disease in Children. <b>2021</b> , 348-382		
54	Thinking out of the box: management of valproic acid toxicity with carbapenems. <i>BMJ Case Reports</i> , <b>2021</b> , 14,	0.9	1
53	The Cerebral Effect of Ammonia in Brain Aging: Blood-Brain Barrier Breakdown, Mitochondrial Dysfunction, and Neuroinflammation. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	O
52	Rapid Rescue From Hyperammonemic Coma After Valproic Acid Poisoning: Dual Therapy With Continuous Renal Replacement Therapy and L-Carnitine Supplementation. <i>Cureus</i> , <b>2021</b> , 13, e15968	1.2	1
51	Role of Carnitine in Non-alcoholic Fatty Liver Disease and Other Related Diseases: An Update. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 689042	4.9	7
50	Non-hyperammonaemia valproate-induced encephalopathy: A case report. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2021</b> ,	2.2	1
49	The role of efflux transporters and metabolizing enzymes in brain and peripheral organs to explain drug-resistant epilepsy. <i>Epilepsia Open</i> , <b>2021</b> ,	4	О
48	Effects of l-carnitine supplementation in patients with childhood-onset epilepsy prescribed valproate. <i>Epilepsy and Behavior</i> , <b>2021</b> , 122, 108220	3.2	1
47	Sodium valproate-related hyperammonaemic encephalopathy. <i>BMJ Case Reports</i> , <b>2014</b> , 2014,	0.9	4
46	[The decreased level of plasma carnitine in patients with epilepsy]. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, <b>2017</b> , 117, 106-110	0.4	3
45	Waddling Gait: A complication of valproate therapy and a thought beyond vitamin D deficiency. <i>Sultan Qaboos University Medical Journal</i> , <b>2020</b> , 20, e104-e108	0.9	1
44	Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update. <i>Current Pharmaceutical Design</i> , <b>2019</b> , 25, 343-351	3.3	22
43	Hyperammonemic Encephalopathy and Lipid Dysmetabolism in a Critically Ill Patient After a Short Course of Amiodarone. <i>The Journal of Critical Care Medicine</i> , <b>2019</b> , 5, 161-165	1.2	3
42	A Case of Valproate Overdose Complicated by Severe Hyperammonemia that was Ameliorated with Time Concomitant with Decline in Serum Valproate Concentration. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , <b>2015</b> , 46, 77-79	Ο	1

41	Valproate-induced hyperammonemic encephalopathy: A reminder of rare complication of valproate. <i>Journal of Emergencies, Trauma and Shock</i> , <b>2011</b> , 4, 321-2	1.2	5
40	Favorable results after conservative management of 316 valproate intoxicated patients. <i>Journal of Research in Medical Sciences</i> , <b>2015</b> , 20, 656-61	1.6	8
39	Valproate induced hyperammonemic encephalopathy treated by haemodialysis. <i>Industrial Psychiatry</i> , <b>2017</b> , 26, 99-102	0.9	3
38	Altered Mental Status and Hyperammonemia after Overdose of Valproic Acid with Therapeutic Valproic Acid Concentrations. <i>International Journal of Clinical Medicine</i> , <b>2014</b> , 05, 546-549	0.3	1
37	A case of food allergy presenting with hypocalnitinemia and elevated serum creatine kinase levels during the treatment with strict elimination diets. <i>Nihon Shoni Arerugi Gakkaishi the Japanese Journal of Pediatric Allergy and Clinical Immunology</i> , <b>2011</b> , 25, 133-137	0.1	
36	Anticonvulsants Used in Child and Adolescent Psychiatric Disorders. 261-299		
35	Enzephalopathien als Folge von Epilepsien und Antikonvulsiva bei Erwachsenen. 2013, 383-390		
34	Valproic Acid Reduces Reactive Oxygen Species in Fibroblast of X-linked Adrenoleukodystrophy. Journal of the Korean Child Neurology Society, <b>2015</b> , 23, 45-50		
33	Lacosamide-associated Valproic Acid Toxicity Following Febrile Illness. <i>Journal of the Korean Child Neurology Society</i> , <b>2016</b> , 24, 63-66		
32	2010🛮 016 y <del>ll</del> ar aras nda Dcuk acil poliklini Inde valproik asit intoksikasyonu nedeniyle takip ve tedavi edilen olgular nde Brlendirilmesi. <i>Konuralp Tip Dergisi</i> ,		
31	The Influence of Ketogenic Diet on Liver Function in Children and Adolescents with Intractable Epilepsy. <i>Journal of Comprehensive Pediatrics</i> , <b>2017</b> , In Press,	0.7	
30	Dihydrolipoamide dehydrogenase, pyruvate oxidation, and acetylation-dependent mechanisms intersecting drug iatrogenesis. <i>Cellular and Molecular Life Sciences</i> , <b>2021</b> , 78, 7451-7468	10.3	О
29	The Effect of Carnitine Supplementation on Hyperammonemia and Carnitine Deficiency Treated with Valproic Acid in a Psychiatric Setting. <i>Innovations in Clinical Neuroscience</i> , <b>2015</b> , 12, 18-24	1	5
28	[Mitochondrial diseases and epilepsy]. Chinese Journal of Contemporary Pediatrics, 2017, 19, 502-504	0.8	
27	L-carnitine does not improve valproic acid poisoning management: a cohort study with toxicokinetics and concentration/effect relationships <i>Annals of Intensive Care</i> , <b>2022</b> , 12, 7	8.9	O
26	Hyperammonemia during treatment with valproate in critically ill patients <i>Clinical Neurology and Neurosurgery</i> , <b>2021</b> , 212, 107092	2	
25	Novel Therapies for the Treatment of Drug-Induced Liver Injury: A Systematic Review <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 785790	5.6	3
24	Method of Preparing Blood Samples on Solid Sorbents for Quantitative Determination of Valproic Acid with Gas Chromatography and Mass Spectrometric Detection. <b>2021</b> , 457-464		

23	Embryonic Hypotaurine Levels Contribute to Strain-Dependent Susceptibility in Mouse Models of Valproate-Induced Neural Tube Defects <i>Frontiers in Cell and Developmental Biology</i> , <b>2022</b> , 10, 832492	5.7	1
22	The Role of l-Carnitine in Mitochondria, Prevention of Metabolic Inflexibility and Disease Initiation <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.3	6
21	Non-Hepatic Hyperammonemia: A Potential Therapeutic Target for Sepsis-Associated Encephalopathy CNS and Neurological Disorders - Drug Targets, 2021,	2.6	1
20	Research Progress on the Effect of Epilepsy and Antiseizure Medications on PCOS Through HPO Axis <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 787854	5.7	O
19	Undifferentiated non-hepatic hyperammonemia in the ICU: Diagnosis and management <i>Journal of Critical Care</i> , <b>2022</b> , 70, 154042	4	1
18	First seizure: is it epilepsy?. 1-2		
17	Case Report: A Case of Valproic Acid-Induced Hyperammonemic Encephalopathy Associated With the Initiation of Lithium: A Re-duplicable Finding <i>Frontiers in Psychiatry</i> , <b>2022</b> , 13, 875636	5	0
16	N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review. <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13,	5.6	1
15	Protective effects of L-carnitine against valproic acid-induced memory impairment and anxiety-like behavior in adult rat. <i>Physiology and Behavior</i> , <b>2022</b> , 253, 113853	3.5	O
14	Nonlinear Pharmacokinetics: Positive Deviation from Linearity. <b>2022</b> , 694-698		
13	Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review.		0
12	Carnitine Deficiency after Long-Term Continuous Renal Replacement Therapy. <b>2022</b> , 2022, 1-4		
11	Long-term Effects of Antiseizure Medications.		0
10	Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises. <b>2022</b> , 108301		O
9	Valproic Acid Overdose: Case Report and Literature Review. 2022,		O
8	The serum acylcarnitines profile in epileptic children treated with valproic acid and the protective roles of peroxisome proliferator-activated receptor a activation in valproic acid-induced liver injury. 13,		O
7	Drug-induced mitochondrial impairment: Mechanisms and testing systems. 2023, 49-76		0
6	Determination of valproic acid and its six metabolites in human serum by LCMS/MS and application to interaction with carbapenems in epileptic patients.		O

5	The musculoprotective effects of thymoquinone on ameliorating muscle damage induced by valproic acid in rats.	О
4	Examination of the emerging role of transporters in the assessment of nephrotoxicity. 1-18	O
3	Metabolomic profiling of triple negative breast cancer cells suggests that valproic acid can enhance the anticancer effect of cisplatin. 10,	1
2	Therapeutic and Toxic Effects of Valproic Acid Metabolites. <b>2023</b> , 13, 134	О
1	Valproate-Induced Encephalopathy Presenting at Therapeutic Blood Concentrations: A Case Report and Literature Review. <b>2023</b> .	О